Perceive Biotherapeutics, Inc. has closed a $15M Series A funding round to advance novel neuroprotective therapeutics for glaucoma & other retinal diseases. Read more on our website at: https://bit.ly/3CXD0OG
RD Fund
学术研究
Raleigh，NC 921 位关注者
Mission-related investments to drive research into preventions, treatments and cures for blinding retinal diseases.
关于我们
The Retinal Degeneration Fund (RD Fund), a 501(c)(3) not-for-profit subsidiary of the Foundation Fighting Blindness, was established in 2018 to serve the Foundation’s mission to rapidly drive research toward preventions, treatments and cures for the entire spectrum of blinding retinal diseases—including retinitis pigmentosa, macular degeneration, and Usher syndrome. RD Fund focuses on mission-related investments in companies with projects nearing clinical testing.
- 网站
-
https://www.RDFund.org
RD Fund的外部链接
- 所属行业
- 学术研究
- 规模
- 2-10 人
- 总部
- Raleigh，NC
- 类型
- 非营利机构
- 创立
- 2018
地点
-
主要
获取路线
223 S. West Street
Suite 900
US，NC，Raleigh
RD Fund员工
动态
-
Nacuity Pharmaceuticals granted U.S. FDA fast track designation for NPI-001 (N-acetylcysteine amide) tablets for the treatment of retinitis pigmentosa. Read more on our website at: https://bit.ly/3E3pfhv
-
Nippon Shinyaku and Atsena Therapeutics have entered into an exclusive strategic collaboration for ATSN-101 in the U.S. and Japan. Read more at: https://bit.ly/4eoDH0c
-
The RD Fund has announced Ocuphire Pharma’s acquisition of Opus Genetics. Learn more at: https://bit.ly/3YAMW8W
-
Ocuphire Pharma announced this week the acquisition of Opus Genetics. The combined company will be renamed Opus Genetics, Inc., effective today, and will trade on Nasdaq under the ticker symbol “IRD” effective October 24, 2024. Read more at: https://bit.ly/4e07tbx
-
SparingVision announced the presentation of positive, longer-term safety data from the Phase I/II PRODYGY clinical trial of its lead investigational therapy SPVN06 for the treatment of retinitis pigmentosa (RP). Read more on our website at: https://bit.ly/4dhoLQW
-
RD Fund转发了
Atsena Therapeutics has?received Rare Pediatric Disease designation?(RPD) from the FDA for ATSN-201, its investigational gene therapy candidate, to treat X-linked retinoschisis (XLRS). Learn more on Glance: https://lnkd.in/erV7Pzdc #GlanceNews Patrick Ritschel
-
Ascidian Therapeutics announced a research collaboration and licensing agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases. Read more on our website at: https://bit.ly/4emlTnL
-
Opus Genetics announced it has received $1.7 million in project-based funding from the Foundation Fighting Blindness to help advance two preclinical candidate programs. Read more on our website at: https://bit.ly/4cljQyd
-
Atsena Therapeutics announces positive clinical data from the first cohort of Phase I/II Trial evaluating ATSN-201 gene therapy for the treatment of X-linked retinoschisis (XLRS). Read more on our website at: https://bit.ly/3QsRqtP